{
  "meta": {
    "title": "Diabetes_And_Obesity",
    "url": "https://brainandscalpel.vercel.app/diabetes-and-obesity-549a4add.html",
    "scrapedAt": "2025-11-30T08:49:05.417Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Improve glycemic control</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Decrease fatty liver disease</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase circulating triglyceride levels</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Decrease insulin resistance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old female presents to the clinic with a history of severe insulin resistance, hyperglycemia, and hypertriglyceridemia. Her physical examination reveals significant loss of subcutaneous fat with hepatomegaly. She has been started on leptin-replacement therapy.<br>Which of the following is NOT a benefit of leptin-replacement therapy in patients with generalized lipodystrophy?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501096a8990fe-8110-4fb5-9cc8-df30824fa38d.jpg\"></span></p>",
      "unique_key": "DT1295394",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295394,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Improve glycemic control (Option A)- Correct benefit.</strong> Leptin-replacement therapy improves <strong>glycemic control</strong> in patients with generalized lipodystrophy by reducing insulin resistance and enhancing glucose uptake by peripheral tissues.</li>\r\n<li><strong>Decrease fatty liver disease (Option B)- Correct benefit.</strong> Leptin therapy has been shown to <strong>reduce hepatic steatosis</strong> (fatty liver disease) in these patients by normalizing lipid metabolism and reducing fat accumulation in the liver.</li>\r\n<li><strong>Increase circulating triglyceride levels (Option C)- Incorrect statement.</strong> Leptin therapy <strong>decreases circulating triglyceride levels,</strong> improving the lipid profile in patients with lipodystrophy. The loss of adipose tissue in lipodystrophy disrupts normal fat metabolism, but leptin therapy helps regulate lipid levels.</li>\r\n<li><strong>Decrease insulin resistance (Option D)- Correct benefit.</strong> Leptin-replacement therapy helps <strong>reduce insulin resistance,</strong> which is a major contributor to the metabolic abnormalities seen in generalized lipodystrophy. This results in improved glucose metabolism and reduced hyperglycemia.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Leptin-replacement therapy </strong>in patients with generalized lipodystrophy helps improve metabolic parameters by enhancing <strong>glycemic control, reducing fatty liver disease, lowering triglyceride levels,</strong> and <strong>decreasing insulin resistance.</strong></li>\r\n<li>This therapy addresses the deficiency of leptin, a hormone essential for regulating energy balance, lipid metabolism, and insulin sensitivity.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased insulin sensitivity</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased insulin resistance</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased insulin resistance</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Lower ectopic fat accumulation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Individuals with high levels of visceral fat are generally at higher risk for Type 2 Diabetes (T2D) due to:</span></p>",
      "unique_key": "DT1295396",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295396,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Increased insulin sensitivity (Option A): </strong> Insulin sensitivity refers to how effectively cells respond to insulin. In people with high visceral fat, insulin sensitivity is generally reduced, not increased.</li>\r\n<li><strong>Decreased insulin resistance (Option B): </strong> Insulin resistance refers to the reduced ability of cells to respond to insulin. High visceral fat is associated with <strong>increased </strong>insulin resistance, not decreased.</li>\r\n<li><strong>Increased insulin resistance (Option C): Visceral fat</strong> produces various adipokines and inflammatory cytokines that contribute to <strong>increased insulin resistance, </strong>a key factor in the pathogenesis of Type 2 Diabetes. Increased visceral fat leads to impaired glucose metabolism and higher fasting glucose levels, making individuals more prone to T2D.</li>\r\n<li><strong>Lower ectopic fat accumulation (Option D):</strong> Ectopic fat accumulation (fat deposition in non-adipose tissues like liver and muscle) tends to increase with high levels of visceral fat, further promoting insulin resistance and metabolic dysfunction.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Visceral fat </strong>is metabolically active and contributes to <strong>increased insulin resistance,</strong> a key determinant in the development of Type 2 Diabetes.</li>\r\n<li><strong>Adipokines </strong>and <strong>pro-inflammatory cytokines</strong> secreted by visceral fat play a crucial role in worsening insulin resistance and metabolic syndrome.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin resistance in peripheral tissues</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Defective insulin secretion in response to glucose</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased glucose uptake in muscle</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased glucose production by the liver</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The four cardinal abnormalities consistently demonstrated in persons with Type 2 Diabetes (T2D) include all EXCEPT:</span></p>",
      "unique_key": "DT1295401",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295401,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Insulin resistance in peripheral tissues (Option A): Correct abnormality.</strong> Insulin resistance, particularly in muscle, liver, and fat cells, is a hallmark of T2D, contributing to impaired glucose uptake and metabolism.</li>\r\n<li><strong>Defective insulin secretion in response to glucose (Option B): Correct abnormality.</strong> In T2D, pancreatic beta cells show impaired insulin secretion in response to glucose, leading to inadequate control of blood sugar levels.</li>\r\n<li><strong>Decreased glucose uptake in muscle (Option C): Correct abnormality.</strong> In T2D, insulin resistance leads to reduced glucose uptake by muscles, further worsening hyperglycemia.</li>\r\n<li><strong>Decreased glucose production by the liver (Option D):</strong> In T2D, the liver <strong>increases</strong> glucose production due to insulin resistance, contributing to fasting hyperglycemia and exacerbating the condition. The correct abnormality is <strong>increased</strong> glucose production by the liver.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>four cardinal abnormalities </strong>in T2D are <strong>insulin resistance, defective insulin secretion, decreased glucose uptake in muscle,</strong> and <strong>increased hepatic glucose production.</strong></li>\r\n<li><strong>Increased glucose production by the liver </strong>is a major contributor to the fasting hyperglycemia observed in T2D.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Elderly patients over 65 years</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Middle-aged adults</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Younger patients in the first 2 to 3 decades of life</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Only during pregnancy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Monogenic forms of diabetes are usually diagnosed in:</span></p>",
      "unique_key": "DT1295405",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295405,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Elderly patients over 65 years (Option A): </strong>Monogenic diabetes is not typically diagnosed in the elderly. This age group more commonly develops Type 2 Diabetes.</li>\r\n<li><strong>Middle-aged adults (Option B):</strong> Although Type 2 Diabetes often appears in middle-aged adults, monogenic diabetes usually presents much earlier.</li>\r\n<li><strong>Younger patients in the first 2 to 3 decades of life (Option C):</strong> Monogenic forms of diabetes, such as <strong>Maturity-Onset Diabetes of the Young (MODY)</strong>, are typically diagnosed in children, adolescents, and young adults, often before the age of 25. These conditions are caused by single gene mutations affecting insulin production.</li>\r\n<li><strong>Only during pregnancy (Option D): </strong>While <strong>Gestational Diabetes Mellitus (GDM)</strong> occurs during pregnancy, monogenic diabetes is not limited to this period. Monogenic diabetes can present at any point during the first two or three decades of life.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Monogenic diabetes </strong>is distinct from Type 1 and Type 2 Diabetes and typically presents in <strong>younger individuals,</strong> often in childhood or early adulthood.</li>\r\n<li>The most common form of monogenic diabetes is <strong>Maturity-Onset Diabetes of the Young (MODY),</strong> characterized by non-autoimmune, inherited defects in insulin production.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin resistance</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Acanthosis nigricans</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperandrogenism</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Severe intrauterine growth retardation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Type A insulin resistance is characterized by all of the following EXCEPT:</span></p>",
      "unique_key": "DT1295409",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295409,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Type A Insulin Resistance</strong>:</p>\r\n<p>Type A insulin resistance is a rare disorder, predominantly seen in <strong>young women,</strong> characterized by significant <strong>insulin resistance, hyperinsulinemia,</strong> and <strong>hyperandrogenism.</strong> It is caused by mutations in the <strong>insulin receptor gene,</strong> leading to impaired insulin signaling.</p>\r\n<p><strong>Key Features:</strong></p>\r\n<ol>\r\n<li><strong>Insulin Resistance:</strong>\r\n<ul>\r\n<li>This is the hallmark of the condition. Despite high circulating levels of insulin, target tissues (such as liver, muscle, and fat) are unresponsive to insulin's action.</li>\r\n<li>This results in hyperglycemia, though not all patients develop frank diabetes immediately. The body compensates for this insulin resistance by secreting more insulin (hyperinsulinemia).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Acanthosis Nigricans:</strong>\r\n<ul>\r\n<li>This skin condition is characterized by dark, thick, velvety patches of skin typically found in body folds (e.g., neck, armpits). It is a common cutaneous marker of <strong>hyperinsulinemia </strong>seen in Type A insulin resistance and other insulin resistance syndromes.</li>\r\n<li>The excess insulin stimulates keratinocytes and dermal fibroblasts, leading to this skin change.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hyperandrogenism:</strong>\r\n<ul>\r\n<li>Due to the insulin resistance and hyperinsulinemia, there is an overproduction of androgens (male hormones) by the ovaries. This leads to <strong>hyperandrogenism,</strong> resulting in signs such as:\r\n<ul>\r\n<li><strong>Hirsutism</strong>(excessive hair growth in a male pattern)</li>\r\n<li><strong>Acne</strong></li>\r\n<li><strong>Menstrual irregularities</strong>(oligomenorrhea or amenorrhea)</li>\r\n<li>In some cases, it may present with features resembling <strong>polycystic ovary syndrome (PCOS).</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<ol start=\"4\">\r\n<li><strong>Absence of Severe Intrauterine Growth Retardation:</strong>\r\n<ul>\r\n<li>Unlike more severe forms of insulin receptor defects, such as <strong>Donohue syndrome</strong>(leprechaunism) and <strong>Rabson-Mendenhall syndrome,</strong> Type A insulin resistance does not involve <strong>severe intrauterine growth retardation.</strong></li>\r\n<li><strong>Donohue syndrome </strong>is much more severe, often resulting in death in early infancy due to extreme insulin resistance and associated complications, including growth retardation.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<ol>\r\n<li><strong>Insulin resistance (Option A)- Correct characteristic.</strong> Type A insulin resistance is primarily characterized by severe insulin resistance, particularly in young women.</li>\r\n<li><strong>Acanthosis nigricans (Option B)- Correct characteristic.</strong> Acanthosis nigricans, a skin condition characterized by dark, velvety patches, is commonly seen in patients with Type A insulin resistance due to chronic hyperinsulinemia.</li>\r\n<li><strong>Hyperandrogenism (Option C)- Correct characteristic.</strong> Women with Type A insulin resistance often exhibit hyperandrogenism, leading to clinical signs such as hirsutism and menstrual irregularities.</li>\r\n<li><strong>Severe intrauterine growth retardation (Option D)- Incorrect characteristic.</strong> Severe intrauterine growth retardation is <strong>not</strong> a feature of Type A insulin resistance. It is characteristic of <strong>Donohue syndrome,</strong> a rare and more severe insulin resistance disorder caused by insulin receptor mutations, also known as <strong>leprechaunism.</strong></li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Type A insulin resistance </strong>is characterized by severe insulin resistance, acanthosis nigricans, and hyperandrogenism, predominantly affecting young women.</li>\r\n<li><strong>Donohue syndrome</strong>(leprechaunism), on the other hand, presents with severe intrauterine growth retardation and other severe insulin resistance features from infancy.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Tall stature</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Protuberant abdomen</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal teeth and nails</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Early onset of puberty</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Rabson-Mendenhall syndrome is associated with which of the following features?</span></p>",
      "unique_key": "DT1295412",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295412,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Tall stature (Option A):</strong> Patients with Rabson-Mendenhall syndrome typically present with <strong>growth retardation</strong>, not tall stature, as a result of severe insulin resistance and metabolic dysregulation.</li>\r\n<li><strong>Protuberant abdomen (Option B): </strong>One of the common physical features in patients with Rabson-Mendenhall syndrome is a <strong>protuberant abdomen</strong>. This is often accompanied by insulin resistance-related visceral fat accumulation and metabolic disturbances.</li>\r\n<li><strong>Normal teeth and nails (Option C):</strong> Rabson-Mendenhall syndrome is associated with <strong>dental abnormalities</strong> and <strong>abnormal nails</strong>. Patients often have <strong>dysplastic teeth</strong> and <strong>thick, abnormal nails</strong> due to the syndrome's effects on various tissues and organs.</li>\r\n<li><strong>Early onset of puberty (Option D):</strong> Children with Rabson-Mendenhall syndrome often have <strong>delayed development</strong> and growth issues, including delayed puberty due to severe insulin resistance and metabolic impairment.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Rabson-Mendenhall syndrome </strong>is a rare form of severe congenital insulin resistance associated with growth retardation, <strong>dental and nail abnormalities</strong>, a <strong>protuberant abdomen,</strong> and metabolic disturbances.</li>\r\n<li>It is caused by <strong>mutations in the insulin receptor gene </strong>and is part of a spectrum of insulin resistance syndromes that also include Donohue syndrome (leprechaunism).</li>\r\n</ul>\r\n ",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Severe insulin resistance</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Loss of subcutaneous fat</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypertriglyceridemia</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased adiponectin levels</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Lipodystrophic diabetes is characterized by all of the following EXCEPT:</span></p>",
      "unique_key": "DT1295413",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295413,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Severe insulin resistance (Option A): Correct characteristic.</strong> Lipodystrophic diabetes is associated with <strong>severe insulin resistance</strong> due to the loss of adipose tissue, which plays a key role in storing lipids and regulating insulin sensitivity.</li>\r\n<li><strong>Loss of subcutaneous fat (Option B): Correct characteristic.</strong> One of the hallmark features of lipodystrophy is the <strong>loss of subcutaneous fat</strong>. This leads to ectopic fat deposition in non-adipose tissues like the liver and muscles, contributing to metabolic dysfunction.</li>\r\n<li><strong>Hypertriglyceridemia (Option C): Correct characteristic.</strong> Patients with lipodystrophy frequently exhibit <strong>hypertriglyceridemia</strong> because of defective lipid storage and metabolism, leading to high levels of circulating triglycerides.</li>\r\n<li><strong>Increased adiponectin levels (Option D): Incorrect characteristic.</strong> In lipodystrophy, <strong>adiponectin levels are typically low</strong>. Adiponectin is a hormone produced by adipocytes that helps improve insulin sensitivity. The loss of fat tissue in lipodystrophic patients leads to reduced adiponectin production, worsening insulin resistance and metabolic syndrome.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Lipodystrophic diabetes </strong>is characterized by <strong>severe insulin resistance, loss of subcutaneous fat, hypertriglyceridemia,</strong> and <strong>low adiponectin levels.</strong></li>\r\n<li>The lack of adipose tissue leads to <strong>ectopic fat deposition </strong>and metabolic complications such as insulin resistance, hyperglycemia, and dyslipidemia.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Brain and kidneys</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver and muscle</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Pancreas and spleen</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Heart and lungs</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Ectopic fat accumulation in which organs contributes to increased insulin resistance?</span></p>",
      "unique_key": "DT1295416",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295416,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Brain and kidneys (Option A):</strong> While ectopic fat can potentially affect various organs, fat accumulation in the brain and kidneys does not play a major role in the development of insulin resistance.</li>\r\n<li><strong>Liver and muscle (Option B): Ectopic fat accumulation</strong> in the <strong>liver</strong> and <strong>skeletal muscle</strong> is a major contributor to <strong>insulin resistance</strong>. In the liver, excess fat (hepatic steatosis) leads to increased glucose production and impaired insulin signaling. Similarly, fat deposition in muscle tissue reduces glucose uptake, leading to insulin resistance.</li>\r\n<li><strong>Pancreas and spleen (Option C):</strong> While fat deposition in the pancreas (pancreatic steatosis) can impair insulin secretion, it is not a primary contributor to insulin resistance. The spleen is not typically involved in insulin resistance related to ectopic fat accumulation.</li>\r\n<li><strong>Heart and lungs (Option D):</strong> Ectopic fat in the heart (myocardial fat) can lead to cardiovascular issues, but it is not directly related to insulin resistance. The lungs are not typically affected by ectopic fat in the context of insulin resistance.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Ectopic fat accumulation </strong>in <strong>liver</strong> (hepatic steatosis) and <strong>skeletal muscle</strong> contributes significantly to the development of <strong>insulin resistance,</strong> which is a key factor in metabolic conditions like Type 2 Diabetes.</li>\r\n<li>These organs play a central role in glucose metabolism, and fat deposition interferes with insulin signaling pathways, leading to decreased glucose uptake and increased glucose production.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased glucagon levels</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Very elevated insulin levels</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Impaired gluconeogenesis</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased insulin sensitivity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In patients with Donohue syndrome, episodes of fasting hypoglycemia occur despite severe insulin resistance due to:</span></p>",
      "unique_key": "DT1295419",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295419,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Decreased glucagon levels (Option A):</strong> Glucagon levels are typically not the primary factor in hypoglycemia episodes in Donohue syndrome. These patients often have elevated insulin levels despite insulin resistance.</li>\r\n<li><strong>Very elevated insulin levels (Option B):</strong> In Donohue syndrome, patients have <strong>severely elevated insulin levels</strong> due to a feedback loop resulting from insulin receptor mutations. Despite insulin resistance, the pancreas continues to secrete excessive insulin in an attempt to regulate blood glucose. These very high insulin levels can lead to <strong>hypoglycemic episodes</strong>, particularly during fasting when insulin effects are less opposed by dietary glucose.</li>\r\n<li><strong>Impaired gluconeogenesis (Option C):</strong> Although gluconeogenesis may be impacted, it is not the primary reason for fasting hypoglycemia in Donohue syndrome. The excess insulin, even if functionally ineffective in peripheral tissues, can still suppress gluconeogenesis to some extent.</li>\r\n<li><strong>Increased insulin sensitivity (Option D):</strong> Donohue syndrome is characterized by <strong>severe insulin resistance</strong>, not increased insulin sensitivity. Insulin's effects are limited due to receptor mutations, but the high levels can cause unpredictable hypoglycemic episodes, particularly during fasting.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Donohue syndrome,</strong> also known as <strong>leprechaunism,</strong> is a rare genetic disorder with severe <strong>insulin resistance </strong>due to mutations in the insulin receptor.</li>\r\n<li><strong>Elevated insulin levels </strong>in these patients can lead to paradoxical hypoglycemia, particularly in fasting states, as the body attempts to compensate for insulin resistance by producing excessive insulin.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">SUR1 and Kir6.2</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">GLUT2 and SUR1</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">KCNJ11 and IRS-1</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Kir6.2 and PPAR&gamma;</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The KATP_{ATP}ATP channel in pancreatic &beta;-cells is composed of which two subunits?</span></p>",
      "unique_key": "DT1295428",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295428,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>SUR1 and Kir6.2 (Option A):</strong> The KATP_{ATP}ATP (ATP-sensitive potassium) channel in pancreatic &beta;-cells is composed of two main subunits: <strong>SUR1</strong> (sulfonylurea receptor 1) and <strong>Kir6.2</strong>. SUR1 is a regulatory subunit, while Kir6.2 forms the potassium channel pore. Together, they play a critical role in insulin secretion by responding to intracellular ATP levels, which modulate potassium flow and membrane depolarization, ultimately triggering insulin release.</li>\r\n<li><strong>GLUT2 and SUR1 (Option B):</strong> GLUT2 is a glucose transporter involved in glucose uptake in &beta;-cells but is not part of the KATP_{ATP}ATP channel structure. SUR1 is, however, a component of the KATP_{ATP}ATP channel.</li>\r\n<li><strong>KCNJ11 and IRS-1 (Option C):</strong> While <strong>KCNJ11</strong> is the gene encoding Kir6.2 (the channel subunit), IRS-1 (Insulin Receptor Substrate-1) is involved in insulin signaling pathways, not in the structure of the KATP_{ATP}ATP channel.</li>\r\n<li><strong>2 and PPAR&gamma; (Option D): Incorrect.</strong> Although Kir6.2 is a component of the KATP_{ATP}ATP channel, <strong>PPAR&gamma;</strong> (Peroxisome Proliferator-Activated Receptor gamma) is a nuclear receptor involved in fat metabolism and insulin sensitivity rather than in potassium channel function.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>KATP_{ATP}ATP channel </strong>in pancreatic &beta;-cells is essential for <strong>glucose-stimulated insulin secretion.</strong></li>\r\n<li>It is composed of <strong>SUR1</strong>(regulatory subunit) and <strong>Kir6.2 </strong>(potassium channel pore), encoded by <strong>ABCC8</strong> and <strong>KCNJ11,</strong> respectively.</li>\r\n<li>The channel links cellular energy status (ATP levels) with insulin secretion, enabling &beta;-cells to respond to blood glucose levels effectively.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Mitochondrial DNA mutations</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Changes in sperm epigenetic marks</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Y-chromosome deletions</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Maternal imprinting</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The passage of obesity risk from father to offspring due to environmental exposures is mediated by:</span></p>",
      "unique_key": "DT1295432",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295432,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Mitochondrial DNA mutations (Option A):</strong> Mitochondrial DNA is maternally inherited and thus does not play a role in paternal transmission of obesity risk to offspring.</li>\r\n<li><strong>Changes in sperm epigenetic marks (Option B): Epigenetic changes</strong> in sperm, such as DNA methylation and histone modifications, can be influenced by environmental exposures, including diet and lifestyle factors in the father. These changes do not alter the DNA sequence itself but affect gene expression, potentially increasing the risk of obesity and metabolic disorders in offspring.</li>\r\n<li><strong>Y-chromosome deletions (Option C):</strong> Y-chromosome deletions are linked to male infertility but are not directly associated with the transmission of obesity risk. Additionally, obesity inheritance is not sex chromosome-specific.</li>\r\n<li><strong>Maternal imprinting (Option D):</strong> Maternal imprinting refers to gene expression regulation from maternal alleles. Paternal epigenetic marks on sperm are responsible for the father-to-offspring transmission of obesity risk rather than maternal imprinting.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Environmental exposures </strong>affecting fathers can lead to <strong>epigenetic modifications</strong> in sperm, contributing to the risk of obesity and related metabolic conditions in offspring.</li>\r\n<li>This phenomenon emphasizes the role of <strong>epigenetic inheritance </strong>and highlights how lifestyle factors in one generation can influence health risks in subsequent generations.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Increasing insulin secretion</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreasing insulin secretion</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Enhancing insulin sensitivity</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulating beta-cell proliferation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Calcineurin inhibitors contribute to post-transplant diabetes mellitus primarily by:</span></p>",
      "unique_key": "DT1295438",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295438,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Mechanism of Calcineurin Inhibitors in Post-Transplant Diabetes Mellitus (PTDM):</strong>\r\n<ul>\r\n<li>Calcineurin inhibitors, including <strong>tacrolimus </strong>and <strong>cyclosporine</strong>, are used as immunosuppressants in transplant patients to prevent organ rejection. However, these drugs have significant metabolic side effects.</li>\r\n<li><strong>Calcineurin</strong>is an enzyme crucial for insulin gene expression and &beta;-cell function. It activates the <strong>NFAT (nuclear factor of activated T-cells)</strong> pathway, which is vital for insulin gene transcription and &beta;-cell survival.</li>\r\n<li>Calcineurin inhibitors <strong>block calcineurin</strong>, leading to decreased activation of NFAT, reducing insulin production from pancreatic &beta;-cells and potentially inducing &beta;-cell apoptosis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Effects on Insulin and Glucose Metabolism:</strong>\r\n<ul>\r\n<li>By inhibiting insulin secretion, these drugs can lead to <strong>hyperglycemia</strong>, increasing the risk of developing PTDM.</li>\r\n<li>In addition, calcineurin inhibitors may indirectly cause <strong>insulin resistance </strong>in peripheral tissues, further worsening glucose metabolism in transplant recipients.</li>\r\n<li>This combined effect of <strong>reduced insulin secretion and peripheral insulin resistance </strong>makes calcineurin inhibitors a significant contributor to PTDM.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical Implications:</strong>\r\n<ul>\r\n<li>Patients on calcineurin inhibitors require <strong>regular monitoring of blood glucose </strong>levels, especially during the initial post-transplant period.</li>\r\n<li>Alternative immunosuppressive regimens or adjunctive treatments like <strong>insulin </strong>or <strong>oral hypoglycemic agents</strong> may be necessary to manage hyperglycemia in patients on these drugs.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Table: Drugs and Their Effects on Diabetes and Insulin Metabolism</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010981569d3e-f489-487f-9ff6-1c9d889bc648.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Calcineurin inhibitors </strong>contribute to PTDM primarily by <strong>reducing insulin secretion</strong> due to inhibition of the calcineurin-NFAT pathway, which is essential for &beta;-cell function.</li>\r\n<li>Various drugs, including corticosteroids, thiazides, and atypical antipsychotics, also impair insulin secretion or increase insulin resistance, contributing to diabetes risk in predisposed patients.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Human placental lactogen</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrogen</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Progesterone</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid hormone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which hormone is one placental factor that contributes to maternal insulin resistance during pregnancy?</span></p>",
      "unique_key": "DT1295439",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295439,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Human Placental Lactogen (HPL)</strong>:\r\n<ul>\r\n<li><strong>Primary role: </strong>HPL, also known as <strong>human chorionic somatomammotropin</strong>, is produced by the placenta and plays a major role in <strong>inducing insulin resistance</strong> during pregnancy.</li>\r\n<li><strong>Mechanism: </strong>HPL has an anti-insulin effect that reduces maternal glucose uptake and increases glucose availability in the bloodstream for the fetus.</li>\r\n<li><strong>Outcome: </strong>By decreasing insulin sensitivity in the mother, HPL ensures a steady supply of glucose to the fetus, which is crucial for fetal growth and development.</li>\r\n<li><strong>Clinical significance: </strong>This hormonal effect is beneficial for fetal development but can predispose some women (particularly those with a family history of diabetes or obesity) to <strong>gestational diabetes mellitus (GDM)</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Estrogen</strong>:\r\n<ul>\r\n<li><strong>Role in pregnancy: </strong>Estrogen levels rise during pregnancy to support uterine growth and blood flow to the placenta.</li>\r\n<li><strong>Effect on insulin: </strong>Estrogen does not significantly contribute to maternal insulin resistance.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Progesterone</strong>:\r\n<ul>\r\n<li><strong>Role in pregnancy: </strong>Progesterone maintains the endometrium and prevents premature uterine contractions.</li>\r\n<li><strong>Effect on insulin: </strong>Progesterone does not play a primary role in insulin resistance during pregnancy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Thyroid Hormone</strong>:\r\n<ul>\r\n<li><strong>Role:</strong>Thyroid hormones are essential for metabolism and fetal brain development.</li>\r\n<li><strong>Effect on insulin: </strong>They do not significantly contribute to the development of insulin resistance in pregnancy.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>HPL </strong>is a key placental hormone that promotes <strong>maternal insulin resistance</strong> to increase glucose availability for the fetus.</li>\r\n<li><strong>Gestational diabetes mellitus (GDM) </strong>is a potential outcome in women with higher susceptibility to insulin resistance during pregnancy.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal glucose tolerance</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Impaired fasting glucose</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Impaired glucose tolerance</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetes mellitus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old woman with a family history of diabetes presents for a routine check-up. Her fasting blood glucose is 110 mg/dL, and her 2-hour postprandial glucose following an oral glucose tolerance test (OGTT) is 150 mg/dL. She has a BMI of 28 kg/m2 and reports no symptoms of hyperglycemia.<br>What is the most likely diagnosis based on her glucose levels?</span></p>",
      "unique_key": "DT1295440",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295440,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol><li><strong>Normal Glucose Tolerance (Option A) - Incorrect:</strong><ul><li><strong>Fasting Blood Glucose (FBG): </strong>Normal FBG is <strong>&lt;100 mg/dL (5.6 mmol/L)</strong>.</li><li><strong>2-Hour OGTT: </strong>For normal glucose tolerance, the 2-hour postprandial glucose should be <strong>&lt;140 mg/dL (7.8 mmol/L)</strong> following a 75-gram OGTT.</li><li>In this case, the patient's fasting glucose is elevated above the normal range, and her 2-hour OGTT value of 150 mg/dL exceeds the threshold for normal glucose tolerance.</li></ul></li><li><strong>Impaired Fasting Glucose (Option B) - Incorrect:</strong><ul><li><strong>Definition: </strong>Impaired fasting glucose (IFG) is a state of <strong>pre-diabetes</strong> characterized by mildly elevated fasting blood glucose levels, indicating insulin resistance or decreased beta-cell function.</li><li><strong>Diagnostic Criteria for IFG: </strong>Fasting glucose levels between <strong>100-125 mg/dL (5.6-6.9 mmol/L)</strong> indicate IFG.</li><li><strong>2-Hour OGTT: </strong>For a diagnosis of isolated IFG, the 2-hour postprandial glucose should be <strong>&lt;140 mg/dL</strong> following OGTT.</li><li>While the patient's fasting glucose falls within the IFG range, her 2-hour OGTT result of 150 mg/dL is higher than the limit for IFG, excluding this diagnosis.</li></ul></li><li><strong>Impaired Glucose Tolerance (Option C) - Correct:</strong><ul><li><strong>Definition: </strong>Impaired glucose tolerance (IGT) is another form of <strong>pre-diabetes</strong> and is diagnosed based on elevated 2-hour glucose levels after an OGTT.</li><li><strong>Diagnostic Criteria for IGT: </strong>A 2-hour postprandial glucose level of <strong>140-199 mg/dL (7.8-11.0 mmol/L)</strong> following a 75-gram OGTT indicates IGT.</li><li><strong>Fasting Glucose: </strong>Individuals with IGT may have normal or slightly elevated fasting glucose levels. In this case, the patient's 2-hour OGTT result of 150 mg/dL fits within the IGT range, making this the correct diagnosis.</li></ul></li><li><strong>Diabetes Mellitus (Option D) - Incorrect:</strong><ul><li><strong>Diagnostic Criteria for Diabetes:</strong><ul><li><strong>Fasting Blood Glucose: </strong>&ge;126 mg/dL (7.0 mmol/L) on two separate occasions.</li><li><strong>2-Hour OGTT: </strong>&ge;200 mg/dL (11.1 mmol/L) following a 75-gram OGTT.</li><li><strong>HbA1c: </strong>An HbA1c level of &ge;6.5%.</li></ul></li><li>Since the patient's fasting and 2-hour postprandial glucose levels are below the diabetic thresholds, a diagnosis of diabetes mellitus cannot be made.</li></ul></li></ol><p><strong>Key Diagnostic Criteria for Glucose Tolerance:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010922fe896a-e794-4fe4-b3ef-70a1c2292645.jpg\"><p><strong>Key Takeaways:</strong></p><ul><li><strong>Pre-diabetes </strong>includes both <strong>IFG</strong> and <strong>IGT</strong>. Each represents an elevated risk for developing Type 2 diabetes and cardiovascular disease.</li><li><strong>OGTT </strong>is the preferred test for diagnosing IGT, while isolated fasting hyperglycemia is indicative of IFG.</li><li>An <strong>HbA1c of 5.7-6.4% </strong>indicates pre-diabetes, but confirmation with fasting glucose or OGTT is typically recommended for accuracy.</li></ul> ",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Presence of pancreatic autoantibodies</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive family history with an autosomal dominant pattern of diabetes inheritance</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Evidence of insulin resistance</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Onset of symptoms in late adulthood</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old male presents to the clinic for a routine evaluation after recent lab results showed elevated blood glucose levels. He reports no symptoms of hyperglycemia, such as polyuria or polydipsia, and has a BMI within the normal range. He does not have a history of diabetic ketoacidosis and has no history of obesity. His family history reveals that his mother and maternal grandfather were diagnosed with diabetes in their early twenties and have been managed on oral hypoglycemic agents rather than insulin.<br>On examination, the patient's fasting blood glucose is 135 mg/dL, and his HbA1c is 6.8%. An oral glucose tolerance test shows a 2-hour glucose of 190 mg/dL. Given the family history, early onset of hyperglycemia without obesity, and relatively mild hyperglycemia.<br>Which of the following findings would most likely pathology confirms the diagnosis?</span></p>",
      "unique_key": "DT1295442",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295442,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol><li><strong>Presence of pancreatic autoantibodies (Option A) - Incorrect:</strong><ul><li><strong>Explanation: </strong>MODY is a monogenic, non-autoimmune form of diabetes. Unlike Type 1 diabetes, patients with MODY do not have autoimmune markers, such as GAD65 or islet cell antibodies. The absence of autoantibodies helps differentiate MODY from autoimmune diabetes.</li></ul></li><li><strong>Positive family history with an autosomal dominant pattern of diabetes inheritance (Option B) - Correct:</strong><ul><li><strong>Explanation: </strong>MODY typically follows an <strong>autosomal dominant inheritance pattern</strong>. This means that the condition is often seen in multiple generations, with early-onset diabetes in each generation. A family history of diabetes, especially in lean individuals without insulin resistance, supports the diagnosis of MODY.</li><li><strong>Genetics: </strong>MODY is caused by single-gene mutations (e.g., HNF1A, GCK) that impair beta-cell function or glucose metabolism. Genetic testing is required to confirm the mutation and MODY subtype.</li></ul></li><li><strong>Evidence of insulin resistance (Option C) - Incorrect:</strong><ul><li><strong>Explanation: </strong>MODY generally presents with <strong>normal insulin sensitivity</strong>. Patients with MODY are not typically insulin-resistant, unlike those with Type 2 diabetes. Insulin resistance is rare in young, lean patients with MODY.</li></ul></li><li><strong>Onset of symptoms in late adulthood (Option D) - Incorrect:</strong><ul><li><strong>Explanation: </strong>MODY usually presents in <strong>adolescence or early adulthood</strong> (before 25 years of age) with mild hyperglycemia, often asymptomatic or detected incidentally. Onset in late adulthood is more suggestive of Type 2 diabetes.</li></ul></li></ol><p><strong>Key Points for Diagnosing MODY:</strong></p><ul><li><strong>Age of Onset: </strong>Typically presents before age 25 but can vary depending on the MODY subtype.</li><li><strong>Family History: </strong>Autosomal dominant inheritance pattern with diabetes in successive generations.</li><li><strong>Insulin Sensitivity: </strong>Generally normal; patients are often lean without insulin resistance.</li><li><strong>Autoantibodies: </strong>Absent, distinguishing MODY from Type 1 diabetes.</li><li><strong>Genetic Testing: </strong>Identifies specific gene mutations associated with MODY subtypes (e.g., HNF1A, GCK, HNF4A).</li></ul><p><strong>Table: Characteristics of Diabetes Types</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010961cbd8b0-1872-42cd-aa8f-5ab3c2bffa91.jpg\"><p><strong>Key Takeaways:</strong></p><ul><li>MODY is a <strong>monogenic form of diabetes </strong>that usually presents in young, lean individuals without insulin resistance.</li><li><strong>Family history </strong>with an autosomal dominant inheritance pattern and early-onset diabetes is highly suggestive.</li><li><strong>Genetic testing </strong>is essential for confirming MODY and determining the subtype, which guides management.</li></ul> ",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Premeal</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Post-exercise</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Bedtime</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Middle of the night</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">When glucose control is poor, initial self-monitoring of blood glucose (SMBG) should concentrate on measuring glucose levels at what times?</span></p>",
      "unique_key": "DT1295444",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295444,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Premeal (Option A):</strong> For patients with poor glucose control, focusing on <strong>premeal blood glucose measurements</strong> provides critical information about baseline glucose levels. Monitoring premeal glucose helps assess the effectiveness of basal insulin or background therapies and allows adjustments to ensure target glucose levels before meals, which can improve overall glycemic control.</li>\r\n<li><strong>Post-exercise (Option B):</strong> While post-exercise glucose levels can provide insights into the body's response to physical activity, they are not the primary focus in cases of poor baseline glucose control. Exercise can cause glucose fluctuations, so premeal readings are prioritized for initial adjustments.</li>\r\n<li><strong>Bedtime (Option C):</strong> Bedtime readings are helpful in preventing overnight hypoglycemia, but focusing initially on premeal measurements provides more actionable data for establishing control, as it directly impacts postprandial glucose excursions.</li>\r\n<li><strong>Middle of the night (Option D):</strong> Middle-of-the-night checks may be necessary for patients at risk of nocturnal hypoglycemia, but they are not typically the focus for initial SMBG when glucose control is poor. Premeal monitoring remains the priority for establishing stable control.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Premeal glucose monitoring </strong>is essential when glucose control is poor, as it provides baseline information for adjusting insulin or other treatments.</li>\r\n<li>Effective premeal monitoring helps reduce <strong>postprandial spikes </strong>and enables more stable glucose management overall.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">70 mg/dL (3.9 mmol/L)</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">65 mg/dL (3.6 mmol/L)</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">60 mg/dL (3.3 mmol/L)</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">54 mg/dL (3.0 mmol/L)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Level 2 hypoglycemia, considered clinically significant, is defined by the ADA as glucose levels at or below:</span></p>",
      "unique_key": "DT1295447",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295447,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>70 mg/dL (3.9 mmol/L) (Option A):</strong> This level represents <strong>Level 1 hypoglycemia</strong> according to the American Diabetes Association (ADA), which is considered a \"low\" but not clinically significant hypoglycemia threshold. Level 1 hypoglycemia requires monitoring but does not indicate a severe risk.</li>\r\n<li><strong>65 mg/dL (3.6 mmol/L) (Option B):</strong> Although this level indicates hypoglycemia, it does not meet the ADA's threshold for <strong>Level 2 hypoglycemia</strong>, which is specifically defined as &le;54 mg/dL.</li>\r\n<li><strong>60 mg/dL (3.3 mmol/L) (Option C):</strong> Like Option B, this value reflects hypoglycemia but does not reach the clinically significant threshold of Level 2.</li>\r\n<li><strong>54 mg/dL (3.0 mmol/L) (Option D):</strong> According to the ADA, <strong>Level 2 hypoglycemia</strong> is defined as a blood glucose level of <strong>54 mg/dL (3.0 mmol/L) or below</strong>. This threshold is considered <strong>clinically significant hypoglycemia</strong>, necessitating immediate treatment to avoid potential serious health risks, especially in patients with diabetes on insulin or other hypoglycemic agents.</li>\r\n</ol>\r\n<p><strong>Detailed Explanation:</strong></p>\r\n<ol>\r\n<li><strong>ADA Classification of Hypoglycemia Levels:</strong>\r\n<ul>\r\n<li><strong>Level 1 Hypoglycemia:</strong> Blood glucose of <strong>70-54 mg/dL (3.9-3.0 mmol/L),</strong> considered \"low\" but not immediately dangerous.</li>\r\n<li><strong>Level 2 Hypoglycemia:</strong> Blood glucose <strong>&le;54 mg/dL (3.0 mmol/L),</strong> classified as <strong>clinically significant hypoglycemia.</strong> This level requires immediate treatment to avoid further decline and symptoms.</li>\r\n<li><strong>Level 3 Hypoglycemia:</strong> Defined by a severe event with <strong>altered mental status or physical incapacity </strong>requiring assistance from another person, irrespective of blood glucose level. This is often associated with more severe symptoms, such as unconsciousness or seizures.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Pathophysiology of Hypoglycemia:</strong>\r\n<ul>\r\n<li>Hypoglycemia occurs when <strong>blood glucose levels fall below the normal range,</strong> leading to insufficient glucose supply to the brain, which relies on glucose as its primary fuel.</li>\r\n<li><strong>Causes </strong>include excess insulin (from injections or oral hypoglycemics), inadequate food intake, increased physical activity, or alcohol consumption without adequate food.</li>\r\n<li>The body's counter-regulatory hormones (epinephrine, glucagon, cortisol) typically respond by increasing blood glucose. However, in individuals with frequent hypoglycemia, this response may be blunted, increasing the risk of severe episodes.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Symptoms of Hypoglycemia:</strong>\r\n<ul>\r\n<li><strong>Mild Hypoglycemia (Level 1):</strong> Sweating, shakiness, palpitations, hunger, and anxiety.</li>\r\n<li><strong>Moderate to Severe Hypoglycemia (Level 2 &amp; 3):</strong> Confusion, blurred vision, slurred speech, irritability, and, if untreated, seizures, or unconsciousness.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Treatment of Hypoglycemia:</strong>\r\n<ul>\r\n<li><strong>Immediate Treatment (Rule of 15):</strong>\r\n<ul>\r\n<li>For Level 1 and Level 2 hypoglycemia, consume <strong>15 grams of fast-acting carbohydrate</strong>(e.g., glucose tablets, 4 oz. of juice, or regular soda).</li>\r\n<li>Recheck blood glucose after 15 minutes. If still below 70 mg/dL (3.9 mmol/L), repeat the treatment.</li>\r\n<li>Follow up with a small meal or snack to maintain glucose levels, especially if the next meal is not soon.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Severe Hypoglycemia (Level 3):</strong>\r\n<ul>\r\n<li><strong>Glucagon Injection:</strong> For those unable to consume glucose orally, glucagon is the primary treatment. It is available as an injection or intranasal powder.</li>\r\n<li><strong>Emergency Assistance:</strong> If the patient is unconscious, emergency assistance is required. Caregivers or family members should be trained to administer glucagon.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Preventive Measures:</strong>\r\n<ul>\r\n<li><strong>Adjusting Medications:</strong> Patients with frequent hypoglycemia episodes may need to adjust their insulin regimen or oral hypoglycemic medications in consultation with their healthcare provider.</li>\r\n<li><strong>Continuous Glucose Monitoring (CGM): </strong>CGM devices can alert patients of impending hypoglycemia and allow timely intervention.</li>\r\n<li><strong>Educating Patients and Caregivers:</strong> Education on the signs of hypoglycemia, proper treatment, and recognition of factors that increase risk (e.g., skipped meals, alcohol intake) is essential.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<ol start=\"5\">\r\n<li><strong>Long-Term Management and Prevention:</strong>\r\n<ul>\r\n<li><strong>Diet and Activity Adjustments:</strong> Consuming regular meals with balanced carbohydrates, protein, and fats can help maintain steady glucose levels. Avoid excessive exercise without adjusting food or insulin.</li>\r\n<li><strong>Medication Review:</strong> For those on insulin or sulfonylureas (such as glipizide), which increase hypoglycemia risk, switching to medications with a lower risk (e.g., DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors) may be beneficial.</li>\r\n<li><strong>Recognition of Hypoglycemia Unawareness:</strong> Frequent hypoglycemia can blunt the body&rsquo;s warning signals, leading to <strong>hypoglycemia unawareness.</strong> This requires closer monitoring, potential CGM use, and in some cases, modification of glycemic targets to reduce risk.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Level 2 hypoglycemia </strong>is defined as blood glucose levels <strong>&le;54 mg/dL (3.0 mmol/L)</strong> and is considered clinically significant, requiring immediate action.</li>\r\n<li><strong>The Rule of 15</strong>(15 grams of carbohydrates, wait 15 minutes, and recheck) is a critical protocol for treating mild to moderate hypoglycemia.</li>\r\n<li><strong>Glucagon </strong>is the treatment of choice for severe hypoglycemia when the patient is unable to consume oral glucose.</li>\r\n<li>Preventive strategies, including dietary adjustments, medication review, and CGM, are essential for high-risk patients.</li>\r\n<li>The ADA defines <strong>Level 2 hypoglycemia (clinically significant) </strong>as blood glucose levels <strong>&le;54 mg/dL (3.0 mmol/L).</strong></li>\r\n<li>This level of hypoglycemia requires prompt intervention, as it presents a higher risk of severe symptoms and complications.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 164,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfonylureas and DPP-4 inhibitors</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">GLP-1 receptor agonists or insulin</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Metformin alone</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Alpha-glucosidase inhibitors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">SGLT2 inhibitors are less effective than which of the following for glucose reduction?</span></p>",
      "unique_key": "DT1295452",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295452,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Sulfonylureas and DPP-4 inhibitors (Option A) - Incorrect:</strong>\r\n<ul>\r\n<li><strong>Explanation</strong>: While both sulfonylureas and DPP-4 inhibitors are effective in lowering blood glucose, they generally do not achieve the same magnitude of glucose reduction as GLP-1 receptor agonists or insulin. SGLT2 inhibitors, however, have a comparable glucose-lowering effect to these agents.</li>\r\n</ul>\r\n</li>\r\n<li><strong>GLP-1 receptor agonists or insulin (Option B) - Correct:</strong>\r\n<ul>\r\n<li><strong>Explanation</strong>: <strong>GLP-1 receptor agonists</strong>(e.g., liraglutide, exenatide) and <strong>insulin</strong> are more potent in reducing blood glucose compared to SGLT2 inhibitors. Insulin can be titrated to achieve significant glucose control, and GLP-1 agonists work by enhancing glucose-dependent insulin secretion, delaying gastric emptying, and reducing appetite, making them particularly effective at lowering both fasting and postprandial glucose levels.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Metformin alone (Option C) - Incorrect:</strong>\r\n<ul>\r\n<li><strong>Explanation</strong>: Metformin, a first-line therapy for Type 2 Diabetes, generally provides a modest glucose-lowering effect compared to GLP-1 receptor agonists and insulin. SGLT2 inhibitors offer an additive effect when combined with metformin, but neither alone achieves the glucose reduction potential of GLP-1 receptor agonists or insulin.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Alpha-glucosidase inhibitors (Option D) - Incorrect:</strong>\r\n<ul>\r\n<li><strong>Explanation</strong>: Alpha-glucosidase inhibitors (e.g., acarbose) primarily lower postprandial glucose but are less effective in overall glucose reduction than SGLT2 inhibitors. They work by delaying carbohydrate absorption in the intestine, which has a limited effect compared to insulin or GLP-1 receptor agonists.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Examples of SGLT2 inhibitors:</strong></p>\r\n<ul>\r\n<li><strong>Canagliflozin</strong></li>\r\n<li><strong>Dapagliflozin</strong></li>\r\n<li><strong>Empagliflozin</strong></li>\r\n<li><strong>Ertugliflozin</strong></li>\r\n</ul>\r\n<p><strong>Class Mechanism:</strong></p>\r\n<ul>\r\n<li>SGLT2 inhibitors block the <strong>SGLT2 protein in the proximal renal tubules </strong>of the kidneys, which is responsible for reabsorbing approximately 90% of filtered glucose.</li>\r\n<li>By inhibiting SGLT2, these drugs reduce glucose reabsorption, leading to <strong>increased glucose excretion in the urine</strong>(glucosuria) and a reduction in blood glucose levels.</li>\r\n</ul>\r\n<p><strong>Mechanism of Action</strong></p>\r\n<ol>\r\n<li><strong>Kidney's Role in Glucose Regulation:</strong>\r\n<ul>\r\n<li>In a healthy kidney, SGLT2 transports glucose from the renal tubules back into the bloodstream.</li>\r\n<li>In patients with diabetes, elevated blood glucose levels increase the load on SGLT2, causing the kidneys to reabsorb more glucose, which worsens hyperglycemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Effect of SGLT2 Inhibition:</strong></li>\r\n</ol>\r\n<p><strong>Benefits of SGLT2 Inhibitors</strong></p>\r\n<ol>\r\n<li><strong>Glucose Lowering:</strong>\r\n<ul>\r\n<li>SGLT2 inhibitors provide moderate glucose-lowering effects and are effective as an <strong><strong>add-on therapy</strong></strong>to metformin or other antidiabetic medications.</li>\r\n<li>They are particularly useful in <strong>Type 2 Diabetes patients with cardiovascular and renal comorbidities.</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Cardiovascular Benefits:</strong>\r\n<ul>\r\n<li>Studies like <strong>EMPA-REG OUTCOME (empagliflozin) </strong>and <strong>CANVAS (canagliflozin)</strong> have shown that SGLT2 inhibitors reduce the risk of <strong>cardiovascular mortality,</strong> especially in patients with heart failure.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Renal Protection:</strong>\r\n<ul>\r\n<li>SGLT2 inhibitors help in reducing albuminuria and delaying progression of chronic kidney disease (CKD).</li>\r\n<li><strong>DAPA-CKD (dapagliflozin) </strong>and <strong>CREDENCE (canagliflozin<strong>)</strong></strong> trials demonstrated that SGLT2 inhibitors reduce the risk of worsening kidney function and provide significant renal protection in diabetic and even non-diabetic CKD patients.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Weight Loss:</strong>\r\n<ul>\r\n<li>The caloric loss due to glucose excretion can lead to modest weight reduction, beneficial in overweight or obese Type 2 Diabetes patients.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Blood Pressure Reduction:</strong>\r\n<ul>\r\n<li>The osmotic diuresis effect also leads to a small reduction in blood pressure, beneficial for hypertensive patients.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Side Effects and Precautions</strong></p>\r\n<ol>\r\n<li><strong>Genitourinary Infections:</strong>\r\n<ul>\r\n<li><strong>Genital and urinary tract infections,</strong> especially fungal infections.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Dehydration and Hypotension:</strong>\r\n<ul>\r\n<li>Osmotic diuresis may lead to <strong>dehydration,</strong> hypotension, or dizziness, particularly in elderly patients or those on other diuretics.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Euglycemic Diabetic Ketoacidosis (DKA):</strong>\r\n<ul>\r\n<li>Rarely, SGLT2 inhibitors can lead to <strong>euglycemic diabetic ketoacidosis</strong>(DKA) even when blood glucose levels are not significantly elevated.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Bone Fracture Risk:</strong>\r\n<ul>\r\n<li>Canagliflozin has been associated with an <strong>increased risk of bone fractures,&nbsp;</strong>likely due to altered calcium and phosphate balance. Patients at risk of osteoporosis should be monitored closely.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Amputation Risk:</strong>\r\n<ul>\r\n<li>Canagliflozin was found to have a small increased risk of <strong>lower-limb amputation&nbsp;</strong>in some studies, especially in patients with peripheral vascular disease or neuropathy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Renal Impairment:</strong>\r\n<ul>\r\n<li>SGLT2 inhibitors are not recommended in patients with <strong>significant renal impairment (eGFR &lt; 30 mL/min/1.73m&sup2;), </strong>as their glucose-lowering efficacy diminishes with declining kidney function.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Comparison with Other Antidiabetic Agents</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109318a6102-ff8d-48b3-8786-18d50795251e.jpg\">\r\n<p><strong>Summary of Key Points</strong></p>\r\n<ul>\r\n<li><strong>SGLT2 inhibitors </strong>are effective in <strong>lowering blood glucose</strong> and provide additional benefits in <strong>weight loss, blood pressure reduction, cardiovascular protection, and renal protection.</strong></li>\r\n<li><strong>Main Side Effects:</strong> Genitourinary infections, dehydration, and a risk of euglycemic DKA.</li>\r\n<li><strong>Indicated </strong>especially in Type 2 Diabetes patients with <strong>heart failure or CKD.</strong></li>\r\n<li>They are best used in combination with other antidiabetic agents for comprehensive glucose control and management of comorbidities.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">B &rarr; A &rarr; C &rarr; D &rarr; E</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">A &rarr; B &rarr; D &rarr; C &rarr; E</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">B &rarr; C &rarr; A &rarr; D &rarr; E</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">A &rarr; C &rarr; B &rarr; D &rarr; E</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old man with type 2 diabetes mellitus is being educated about the progression of diabetic nephropathy. Arrange the following events in the correct chronological order from first to last in the development of diabetic nephropathy.<br>A. Onset of microalbuminuria<br>B. Development of glomerular hyperfiltration and renal hypertrophy<br>C. Appearance of overt proteinuria (macroalbuminuria)<br>D. Decline in glomerular filtration rate (GFR) leading to renal insufficiency<br>E. Progression to end-stage renal disease (ESRD)</span></p>",
      "unique_key": "DT1295463",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295463,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The progression of <strong>diabetic nephropathy</strong> in patients with type 2 diabetes typically follows these stages:</p>\r\n<ol>\r\n<li><strong><strong>Development of Glomerular Hyperfiltration and Renal Hypertrophy (B)</strong></strong>:\r\n<ul>\r\n<li><strong>Initial Phase: </strong>In the early years after the onset of diabetes, patients experience an increase in <strong>glomerular filtration rate (GFR)</strong> and kidney size due to <strong>hyperglycemia-induced hemodynamic changes</strong>. This stage, known as glomerular hyperfiltration, is often asymptomatic but sets the stage for further kidney damage.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Onset of Microalbuminuria (A):</strong>\r\n<ul>\r\n<li><strong>Microalbuminuria Stage: </strong>Approximately <strong>5-10 years</strong> after diabetes onset, small amounts of <strong>albumin</strong> start to appear in the urine, detectable as <strong>microalbuminuria.</strong> This stage is a crucial marker of early nephropathy and represents damage to the glomerular filtration barrier. Microalbuminuria is defined as <strong>30-300 mg/day</strong> of albumin in the urine.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Appearance of Overt Proteinuria (Macroalbuminuria) (C):</strong>\r\n<ul>\r\n<li><strong>Progression to Macroalbuminuria: </strong>Microalbuminuria progresses to <strong>macroalbuminuria</strong> (also known as overt proteinuria) as kidney damage becomes more pronounced. Macroalbuminuria is defined as <strong>&gt;300 mg/day</strong> of protein in the urine and indicates significant nephropathy and risk of further kidney function decline.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Decline in GFR Leading to Renal Insufficiency (D):</strong>\r\n<ul>\r\n<li><strong>Progressive Renal Dysfunction: </strong>Persistent proteinuria eventually leads to a <strong>decline in GFR,</strong> indicating progressive kidney damage and renal insufficiency. This stage is marked by a gradual reduction in the filtering capacity of the kidneys, resulting in an increase in serum creatinine and worsening kidney function.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Progression to End-Stage Renal Disease (ESRD) (E):</strong>\r\n<ul>\r\n<li><strong>Final Stage: </strong>Ultimately, continued decline in kidney function progresses to <strong>end-stage renal disease (ESRD),</strong> where the kidneys fail to maintain fluid and electrolyte balance. At this stage, <strong>renal replacement therapy</strong> (dialysis or transplantation) is required to sustain life.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Key Points:</strong></p>\r\n<ol>\r\n<li><strong>Glomerular Hyperfiltration (B): </strong>The earliest stage with increased GFR and kidney hypertrophy due to hyperglycemia-induced hemodynamic changes.</li>\r\n<li><strong>Microalbuminuria (A): </strong>The initial sign of diabetic nephropathy with <strong>30-300 mg/day</strong> albumin in urine, marking early glomerular damage.</li>\r\n<li><strong>Macroalbuminuria (C): </strong>Higher levels of protein in urine <strong>(&gt;300 mg/day),</strong> indicating significant progression of nephropathy.</li>\r\n<li><strong>Decline in GFR (D): </strong>The gradual reduction in kidney filtering capacity leading to renal insufficiency and increased serum creatinine.</li>\r\n<li><strong>End-Stage Renal Disease (E): </strong>Final stage where renal replacement therapy (dialysis or transplant) is necessary due to kidney failure.</li>\r\n</ol>\r\n<p><strong>Additional Notes:</strong></p>\r\n<ul>\r\n<li><strong>Early Detection: </strong>Regular screening for <strong>microalbuminuria</strong> in diabetic patients is critical for early intervention.</li>\r\n<li><strong>Management Strategies: </strong>Tight <strong>glycemic control, blood pressure management</strong> (preferably with ACE inhibitors or ARBs), and <strong>lifestyle modifications</strong> can slow the progression of diabetic nephropathy.</li>\r\n<li><strong>Patient Education: </strong>Understanding the stages of diabetic nephropathy enables patients to adhere to preventive strategies to delay or avoid progression to ESRD.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">1-F, 2-D, 3-A, 4-B, 5-E, 6-J</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-I, 3-H, 4-G, 5-C, 6-E</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">1-H, 2-F, 3-G, 4-D, 5-A, 6-I</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-J, 3-C, 4-E, 5-H, 6-D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following Oral Hypoglycemic Agents in List A with their primary Mechanisms of Action in List B.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109c865f597-692b-401e-b602-42a35d351275.jpg\"></span></p>",
      "unique_key": "DT1295472",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295472,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Comparison Table</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501099da9596b-b9a7-4ce4-a4af-7a6a6764f5e8.jpg\">\r\n<p><strong>Key Takeaways</strong></p>\r\n<ul>\r\n<li><strong>Metformin </strong>is a first-line agent that reduces hepatic glucose production and increases insulin sensitivity, with a favorable effect on weight.</li>\r\n<li><strong>Sulfonylureas (e.g., Glipizide) </strong>promote insulin secretion but come with risks of hypoglycemia and weight gain.</li>\r\n<li><strong>Thiazolidinediones (e.g., Pioglitazone) </strong>increase insulin sensitivity, but side effects include weight gain, edema, and heart failure risk.</li>\r\n<li><strong>DPP-4 Inhibitors (e.g., Sitagliptin) </strong>are often add-ons with a glucose-dependent mechanism, lowering risk of hypoglycemia.</li>\r\n<li><strong>Alpha-Glucosidase Inhibitors (e.g., Acarbose) </strong>are beneficial for controlling post-meal glucose but cause gastrointestinal side effects.</li>\r\n<li><strong>SGLT2 Inhibitors (e.g., Canagliflozin) </strong>enhance glucose excretion through the kidneys, with added benefits for cardiovascular and renal health but have risks like genitourinary infections.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 192,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}